Keyphrases
High Risk
100%
Targeted Treatment
100%
Pembrolizumab
100%
Early-stage Triple-negative Breast Cancer
100%
Triple-negative Breast Cancer
40%
Neoadjuvant Chemotherapy
40%
Randomized Double-blind
20%
Placebo-controlled
20%
Clinical Trials
20%
Young Women
20%
Monotherapy
20%
Chemotherapy Resistance
20%
Targeted Therapy
20%
Chemotherapy
20%
U.S. Food
20%
Paucity
20%
Pathological Complete Response
20%
Complete Response Rate
20%
Breast Cancer Subtypes
20%
Advanced Stage
20%
Chemotherapy Alone
20%
Tumor Microenvironment
20%
Taxanes
20%
Immune Checkpoint Inhibitors
20%
Genomic Landscape
20%
Anthracyclines
20%
Heterogeneous Disease
20%
Treatment Paradigms
20%
Event-free Survival
20%
Immunomodulatory
20%
Genomic Instability
20%
Immune Landscape
20%
Landmark Trials
20%
DNA Repair Deficiency
20%
Immunogenic Tumor
20%
Anti-programmed death-1 Monoclonal Antibody
20%
Women of Color
20%
Immunotherapy Toxicity
20%
Medicine and Dentistry
Targeted Therapy
100%
Triple Negative Breast Cancer
100%
Pembrolizumab
100%
Immunotherapy
33%
Neoadjuvant Chemotherapy
33%
Biological Marker
16%
Prevalence
16%
Clinical Trial
16%
Monotherapy
16%
Placebo
16%
Genomic Instability
16%
Breast Cancer
16%
Event Free Survival
16%
Monoclonal Antibody
16%
DNA Repair
16%
Immune Checkpoint Inhibitor
16%
Tumor Microenvironment
16%
Anthracycline
16%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Pembrolizumab
100%
Chemotherapy
50%
Immunotherapy
33%
Placebo
16%
Clinical Trial
16%
Monotherapy
16%
Biological Marker
16%
Prevalence
16%
Breast Cancer
16%
Monoclonal Antibody
16%
Tumor Microenvironment
16%
Anthracycline
16%
Event Free Survival
16%
Immune Checkpoint Inhibitor
16%
Taxane
16%
Diseases
16%
Immunology and Microbiology
Pembrolizumab
100%
Immunotherapy
40%
Prevalence
20%
DNA Repair
20%
Monoclonal Antibody
20%
Genomic Instability
20%
Event Free Survival
20%
Immune Landscape
20%